13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000078003
Total reported value
$170.4M
$170.4M
18 檔
111.8%
As reported in its official Q1 2026 Form 13F filing, Pfizer Inc's tracked investment portfolio stood at $170.4M with 18 total positions.
In Q1 2026, Pfizer Inc adopted a defensive or profit-taking posture, trimming 5 positions and completely liquidating 1 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including ORIC, ALLO, ARVN) accounted for 111.8% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 24.14% | -22.05% | -11.08% | |
| 2 | ALLO | Allogene Therapeutics Inc | Stock-Other | 20.85% | +6.70% | — | |
| 3 | ARVN | Arvinas Inc | Stock-Other | 14.63% | +1.61% | — | |
| 4 | CELC | Celcuity Inc | Stock-Other | 13.13% | +4.22% | -15.38% | |
| 5 | ✓ | Zura Bio LTD | Stock-Other | 7.05% | -5.36% | -4.41% | |
| 6 | WVE | Wave Life Sciences Ltd. | Stock-Other | 5.00% | +1.42% | — | |
| 7 | PYXS | Pyxis Oncology Inc | Stock-Other | 3.86% | +7.57% | — | |
| 8 | CRBU | Caribou Biosciences Inc | Stock-Other | 3.50% | +1.13% | — | |
| 9 | SPRO | Spero Therapeutics Inc | Stock-Other | 2.31% | +0.82% | — | |
| 10 | BHVN | Biohaven Ltd. | Stock-Other | 1.77% | +2.93% | — | |
| 11 | CRDF | Cardiff Oncology Inc | Stock-Other | 1.57% | +0.20% | — | |
| 12 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.84% | +1.42% | — | |
| 13 | NXTC | Nextcure Inc | Stock-Other | 0.64% | -0.60% | -2.72% | |
| 14 | AGMB | Agomab Therapeutics NV | Stock-Other | 0.34% | +0.27% | — | |
| 15 | QTTB | Q32 Bio Inc | Stock-Other | 0.31% | -0.31% | EXIT | |
| 16 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.06% | +0.02% | — | |
| 17 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.01% | +0.01% | — | |
| 18 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALLO | Allogene Therapeutics Inc | +8.1% | — | Unchanged |
| 2 | ORIC | Oric Pharmaceuticals Inc | +5.5% | -11.08% | Trim |
| 3 | ✓ | Zura Bio LTD | +0.5% | -4.41% | Trim |
| 4 | PYXS | Pyxis Oncology Inc | +0.4% | — | Unchanged |
| 5 | CRBU | Caribou Biosciences Inc | +0.4% | — | Unchanged |
| 6 | ZNTL | Zentalis Pharmaceuticals Inc | +0.3% | — | Unchanged |
| 7 | DNA | Ginkgo Bioworks Holdings Inc | — | — | Unchanged |
| 8 | SENS1GBP | Senseonics Holdings Inc | — | — | Unchanged |
| 9 | BOLT | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 10 | SPRO | Spero Therapeutics Inc | 0% | — | Unchanged |
| 11 | QTTB | Q32 Bio Inc | -0.1% | -63.42% | Trim |
| 12 | NXTC | Nextcure Inc | -0.3% | -2.72% | Trim |
| 13 | BHVN | Biohaven Ltd. | -0.6% | — | Unchanged |
| 14 | CRDF | Cardiff Oncology Inc | -1.3% | — | Unchanged |
| 15 | CELC | Celcuity Inc | -1.6% | -15.38% | Trim |
| 16 | ARVN | Arvinas Inc | -2.7% | — | Unchanged |
| 17 | WVE | Wave Life Sciences Ltd. | -8.5% | — | Unchanged |
| 18 | ANTX | An2 Therapeutics Inc | — | EXIT | Sold out |
| 19 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
According to official SEC Form 13F filings, Pfizer Inc reported a total U.S. public equity portfolio value of $170.4M across 18 disclosed positions in Q1 2026.
During Q1 2026, Pfizer Inc's top holdings by market value included ORIC (24.1%)、ALLO (20.9%)、ARVN (14.6%). The largest single position, ORIC, represented 24.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
AGMB
市值: $813.8K
Top Position Liquidated / Trimmed
ANTX
前期市值: $815.4K
In Q1 2026, Pfizer Inc made 7 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 5 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.